Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 51

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 51
---
 (II) use commercially reasonable efforts to not omit any act, in each case, that would reasonably be expected to prevent, be materially inconsistent with, materially delay or otherwise impede the successful completion of the acquisition of 
 Common Shares by the Purchaser pursuant to the Arrangement;                                                                                                                                                                                     |

| (CC) | not enter into any new line of business; |

| (DD) | except in connection with the Distribution, not reduce the stated capital of the securities of the Company or 
 the Subsidiary;                                                                                               |

| (EE) | except in connection with the Distribution, not reduce the paid-up                      
 capital (as defined in the Tax Act) of the securities of the Company or the Subsidiary; |

| (FF) | not disclose any material trade secrets or material confidential information pertaining to the Company or the                                                  
 Subsidiary to any person, other than to persons who are under a contractual, legal, or ethical obligation to maintain the confidentiality of such information; |

| (GG) | not take any action that would, or would reasonably be expected to prevent, materially delay or otherwise        
 impede the consummation of the Arrangement, or the satisfaction of any of the conditions set forth in Article 8; |

| (HH) | enter into or amend any Contract with any broker, finder or investment banker, provided that the foregoing                                                                                                                     
 shall not prohibit the Company from entering into an agreement on commercially reasonable terms with any dealer and proxy solicitation services firm for purposes of soliciting proxies in connection with the Arrangement; or |

| (II) | not announce an intention, enter into any formal or informal agreement, or otherwise make a commitment to do 
 any of the things prohibited by any of the foregoing subsections.                                            |

| (c) | Notwithstanding the foregoing, the Company shall be entitled, but is under no obligation, to sell, transfer,                                                                                                                                                                                       
 license, assign or otherwise divest any or all of the Company’s and its Subsidiary’s rights, Intellectual Property, and other assets related to (i) the RP-3467 program, a Polq ATPase Inhibitor, (ii) the RP-1664 program, a polo-like kinase 4 (PLK4) inhibitor, (iii) the RP-3500 (Camonsertib) 
 program, an ATR inhibitor, and/or (iv) the AMBER program, a preclinical RBM5 degrader, in one or more transactions